Halozyme Therapeutics Inc (HALO)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Based on the provided data, the days of sales outstanding (DSO) for Halozyme Therapeutics Inc are not available for any of the specified dates from March 31, 2020, to December 31, 2024. The DSO ratio typically indicates the average number of days a company takes to collect revenue after a sale is made. However, without specific values for DSO, it is difficult to assess how efficiently Halozyme Therapeutics is managing its accounts receivable and collecting payments from customers. An analysis of DSO would usually involve tracking changes over time to determine if there are any improving or deteriorating trends in the company's collection cycle. Without this data, a thorough evaluation of the company's liquidity and efficiency in managing its receivables is not feasible.
Peer comparison
Dec 31, 2024